NCT00371007View on ClinicalTrials.gov

MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

June 1, 2004

Primary Completion Date

April 25, 2005

Study Completion Date

April 25, 2005

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks

DRUG

Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00371007 - MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043) | Biotech Hunter | Biotech Hunter